This trial is active, not recruiting.

Condition tuberculosis
Treatment observational
Sponsor Michael Hoelscher
Collaborator Marius Nasta Pulmonology Institute, Bucharest, Rumania
Start date March 2015
End date May 2016
Trial size 400 participants
Trial identifier NCT02382107, LMU-IMPH-Bucharest-01


The diagnosis of tuberculosis (TB) and especially the detection of drug resistance of tuberculosis mycobacteria can be time consuming and costly. New and rapid diagnostic tests are needed to improve early case detection and correct initiation of treatment.

In the planned cross-sectional diagnostic evaluation study the investigators are aiming for the assessment of several new TB diagnostics (e.g. new AID strip assays and TrDNA assay in urine) in TB suspects who are presenting themselves to the pulmonary ambulance (TB dispensary for sector 4) at the Marius Nasta Institute (MNI). The study will be conducted in a co-operation between the MNI and the German Center for Infection Research (DZIF).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective cross-sectional

Primary Outcomes

The main objective is the evaluation of the diagnostic characteristics (sensitivity, specificity) of several new rapid diagnostic tests for TB compared to culture (both liquid and solid) as the reference standard in patients
time frame: Up to 70 days after enrolment

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Subjects with suspected pulmonary TB, who have a chest radiograph which is compatible with pulmonary TB plus one of the signs or symptoms listed below and indicative of possible TB: - Productive cough for more than 2 weeks - Haemoptysis - Fever - Night sweats - Substantial involuntary weight loss - Subject able and willing to give informed consent, including for HIV-testing Exclusion Criteria: - anti-tuberculosis therapy with simultaneous administration of at least 2 active compounds taken currently or within the previous 6 months - physical or mental inability preventing study participation as determined at the discretion of the investigator - member of a vulnerable population group (prisoner, soldier, mental illness, under guardianship, age <18 years) - extrapulmonary tuberculosis without pulmonary involvement - incapability to produce 2 sputum samples of sufficient quality (mucoid) and volume (at least 3ml)

Additional Information

Official title A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania
Principal investigator Elmira Ibraim, MD
Description Up to 400 TB suspects will be consecutively screened for their eligibility for participation in the study. In those who are eligible (according to the criteria listed above) to participate, 2 sputum samples and one urine will be collected for standard diagnostic testing for TB in sputum (smear, Line Probe Assays and culture methods, as defined in the national guidelines) and for the evaluation of the new assays; one blood sample will be collected for analysis of lipoprotein profiles in serum of TB patients. Further, a HIV test and a clinical examination will be performed in all study subjects. Information on risk factors for TB disease (co-morbidities such as diabetes mellitus, co-medication such as steroids and risk behaviour such as smoking) will be also documented. All TB tests results and data which are generated in the study will be collected on standardized study forms and entered in a password-secured data base. TB tests results will be also shared with the medical staff treating the patients who are participating in the study. One follow up visit will be performed after 8 weeks in order to evaluate the clinical progress of the participants, either on TB treatment (if TB was confirmed) or alternative therapy, in participants who were not diagnosed with TB. The isolated TB strains will be sent to the Research Center Borstel in Germany for evaluation through sequencing and phenotypic methods. The remnants of collected samples will be stored in the National TB Laboratory for future evaluations of new tests.
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich.